Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/47747
Title: Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials.
Authors: Zhou K.;Zou D.;Zhou J.;Hu J.;Yang H.;Zhang H.;Ji J.;Xu W.;Jin J.;Lv F.;Feng R.;Gao S.;Zhou D.;Tam C.S.;Simpson D.;Wang M.;Phillips T.J.;Opat S. ;Huang Z.;Lu H.;Song Y.
Institution: (Zhou, Song) Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450003, China
(Zou) Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China
(Zhou) Tongji Hospital, Tongji Medical College, Wuhan 430032, China
(Hu) Fujian Medical University Union Hospital, Fuzhou 35000, China
(Yang) Zhejiang Cancer Hospital, Hangzhou 310000, China
(Zhang) Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
(Ji) West China Hospital of Sichuan University, Chengdu 610041, China
(Xu) The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
(Jin) The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou 310003, China
(Lv) Fudan University Shanghai Cancer Center, Shanghai 200032, China
(Feng) Nanfang Hospital of Southern Medical University, Guangzhou 510515, China
(Gao) The First Hospital of Jilin University, Changchun 130031, China
(Zhou) Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
(Tam) Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC 3065, Australia
(Simpson) North Shore Hospital, Auckland 2065, New Zealand
(Wang) The University of Texas MD Anderson Cancer Center, Houston, TX 78701, United States
(Phillips) University of Michigan, Ann Arbor, MI 48109, United States
(Opat) Monash Health, Monash University, Clayton, VIC 3800, Australia
(Huang, Lu) BeiGene (Beijing) Co., Ltd, Beijing 102206, China
(Song) Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing 100142, China
Issue Date: 4-May-2022
Copyright year: 2021
Publisher: BioMed Central Ltd
Place of publication: United Kingdom
Publication information: Journal of Hematology and Oncology. 14(1) (no pagination), 2021. Article Number: 167. Date of Publication: December 2021.
Journal: Journal of Hematology and Oncology
Abstract: Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a high initial response rate followed almost invariably by relapse. Here we report the pooled data from 2 studies, BGB-3111-AU-003 and BGB-3111-206, to explore the efficacy of zanubrutinib monotherapy in relapsed/refractory (R/R) MCL. A total of 112 patients were included. Median follow-up durations were 24.7 and 24.9 months for BGB-3111-AU-003 and BGB-3111-206, respectively. Overall response rate (ORR) and complete response (CR) rate were 84.8% and 62.5%, and median duration of response, progression-free survival (PFS) and overall survival (OS) were 24.9, 25.8 and 38.2 months, respectively. After weighting, the PFS (median: NE vs. 21.1 months, P = 0.235) and OS (median: NE vs. 38.2 months, P = 0.057) were similar but numerically better in the second-line than later-line group. Zanubrutinib was well-tolerated with treatment discontinuation and dose reduction for adverse events in 12.5% and 2.7% of patients, respectively. Hypertension, major hemorrhage and atrial fibrillation/flutter rates were 11.6%, 5.4% and 1.8%, respectively. Zanubrutinib is efficacious in R/R MCL, with a favorable safety profile.Copyright © 2021, The Author(s).
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1186/s13045-021-01174-3
PubMed URL: 34649571 [https://www.ncbi.nlm.nih.gov/pubmed/?term=34649571]
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/47747
Type: Letter
Subjects: atrial fibrillation autologous stem cell transplantation
brain hemorrhage cancer patient
congestive heart failure drug dose reduction
drug efficacy
drug safety
drug tolerability
drug withdrawal
heart atrium flutter hypertension ischemic stroke mantle cell lymphoma
mantle cell lymphoma
monotherapy
pneumonia progression free survival
traffic accident
bendamustine
cyclophosphamide
dexamethasone
doxorubicin
lenalidomide
vincristine
zanubrutinib
Type of Clinical Study or Trial: Opinion, perspective or news
Appears in Collections:Articles

Show full item record

Page view(s)

18
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.